First Epilepsy Cell Drug Receives US and China Clinical Approval

Shanghai-based Unixell Biotech has received regulatory clearance to begin human clinical trials in both the United States and China for UX-GIP001, an allogeneic induced pluripotent stem cell (iPSC)-derived cell therapy targeting focal epilepsy. The therapy is the first of its kind to reach the clinical stage in both countries.

The U.S. Food and Drug Administration (FDA) granted Investigational New Drug (IND) clearance on March 12, 2026. Subsequently, on April 8, 2026, the National Medical Products Administration in China also approved the therapy for clinical testing.

Addressing Drug-Resistant Epilepsy

Epilepsy is a neurological disorder affecting more than 70 million people globally. It is characterized by abnormal electrical activity in the brain, which can lead to involuntary limb movements and sudden loss of consciousness.

While many patients manage the condition with medication, approximately one-third of patients suffer from intractable or drug-resistant epilepsy. For these individuals, standard treatments—including pharmacological interventions, neurostimulation, and surgical resection—are often ineffective or associated with significant side effects.

UX-GIP001 is designed to provide an alternative for patients who do not respond to traditional therapies by targeting the root source of seizures while attempting to preserve healthy brain tissue.

Mechanism of Action

The therapy leverages Unixell’s proprietary stem cell technology to produce inhibitory neural progenitor cells through a process of directed differentiation. In patients with epilepsy, impaired GABAergic interneurons are believed to drive the neural hyperexcitability that triggers seizures.

UX-GIP001 uses donor-derived, or allogeneic, stem cells that are reprogrammed to produce GABA, the primary chemical messenger responsible for calming the nervous system and the brain.

Once transplanted into the damaged areas of the brain, these cells are intended to reconstruct inhibitory circuits, thereby suppressing the excessive electrical activity and reducing the frequency of seizures.

Preclinical Evidence and Clinical Goals

Preclinical studies conducted in animal models have provided the basis for these human trials. In studies involving mice, researchers observed that approximately 90 percent of seizure-related brain activity had disappeared six months after the implantation of the stem cells.

By the eight-month mark, the reporting indicated that epileptic waves were almost undetectable. These results supported the safety profile and efficacy of the therapy, leading to the current regulatory approvals.

The upcoming Phase 1 study is designed to evaluate the safety, tolerability, and efficacy of UX-GIP001 specifically in patients suffering from drug-resistant epilepsy.

Broader Therapeutic Pipeline

The progression of UX-GIP001 is part of a larger strategic effort by Unixell Biotech to address unmet clinical needs in neurology. The company has established a core product pipeline that targets both epilepsy and Parkinson’s disease.

To cover diverse treatment scenarios and indications, Unixell is advancing a comprehensive matrix of cellular therapy strategies, utilizing both autologous and allogeneic approaches.